Hims & Hers Stock Retreats as Peptide Market Optimism Fades on Regulatory Uncertainty
Hims & Hers stock briefly rallied on reports the FDA may ease peptide restrictions, but gains reversed. The company had proactively acquired a peptide production facility in California in 2025.